184 related articles for article (PubMed ID: 21983399)
1. [Outcome of differentiated thyroid cancer after initial treatment].
Konrády A; Bencsik Z; Locsey Z; Bénik T
Orv Hetil; 2011 Oct; 152(43):1731-8. PubMed ID: 21983399
[TBL] [Abstract][Full Text] [Related]
2. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial.
Schlumberger M; Leboulleux S; Catargi B; Deandreis D; Zerdoud S; Bardet S; Rusu D; Godbert Y; Buffet C; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Toubert ME; Kelly A; Benhamou E; Borget I
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):618-626. PubMed ID: 29807824
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
4. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma.
Franceschi M; Kusić Z; Franceschi D; Lukinac L; Roncević S
J Nucl Med; 1996 Mar; 37(3):446-51. PubMed ID: 8772642
[TBL] [Abstract][Full Text] [Related]
5. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
6. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
7. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
8. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
Baudin E; Do Cao C; Cailleux AF; Leboulleux S; Travagli JP; Schlumberger M
J Clin Endocrinol Metab; 2003 Mar; 88(3):1107-11. PubMed ID: 12629092
[TBL] [Abstract][Full Text] [Related]
9. [Outcomes of long-term combined treatment in follicular thyroid carcinoma].
Baranauskas Z; Valuckas KP; Tiskevicius S
Medicina (Kaunas); 2010; 46(4):268-74. PubMed ID: 20571295
[TBL] [Abstract][Full Text] [Related]
10. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
11. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
[TBL] [Abstract][Full Text] [Related]
12. Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E;
N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127
[TBL] [Abstract][Full Text] [Related]
13. [Use of serum thyroglobulin determination in the follow-up of differentiated carcinomas of the thyroid].
Secades Ariz I; Pérez Piqueras JL; Labanda Tejedor P; Cordero Peinado J
An Med Interna; 1988 Sep; 5(9):439-43. PubMed ID: 2856622
[No Abstract] [Full Text] [Related]
14. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up.
Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H
Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613
[No Abstract] [Full Text] [Related]
15. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
[TBL] [Abstract][Full Text] [Related]
16. [Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma].
Díez JJ; Grande E; Iglesias P
Med Clin (Barc); 2015 Jan; 144(1):35-41. PubMed ID: 24613061
[TBL] [Abstract][Full Text] [Related]
17. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma.
Sawka AM; Orlov S; Gelberg J; Stork B; Dowar M; Shaytzag M; Tabatabaie V; Freeman JL; Walfish PG
Head Neck; 2008 Jun; 30(6):693-700. PubMed ID: 18098308
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]